This Crypto Is Set to Explode in December

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Sharon Benzeno Biography and Net Worth

Insider of Adaptive Biotechnologies

Dr. Sharon Benzeno is the Chief Business Development Officer and leads the Drug Discovery group of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Prior to joining Adaptive in 2014, Sharon was Senior Director at Elsevier Inc., a healthcare informatics company. Prior to Elsevier, Sharon co-led the oncology business unit at Capgemini SE, a consulting and technology services company. Prior to Capgemini, Sharon served in a variety of management roles at AstraZeneca plc. Sharon holds a PhD in Biomedical Sciences from New York University School of Medicine, an MBA in Finance and Leadership from New York University Stern School of Business and a BA in Biochemistry from New York University. Sharon completed a postdoctoral fellowship in cancer biology at the University of Pennsylvania Abramson Cancer Center.

What is Sharon Benzeno's net worth?: The estimated net worth of Sharon Benzeno is at least $144,760.56 as of March 15th, 2021. Dr. Benzeno owns 24,248 shares of Adaptive Biotechnologies stock worth more than $144,761 as of December 18th. This net worth estimate does not reflect any other investments that Dr. Benzeno may own. Additionally, Dr. Benzeno receives a salary of $630,720.00 as Insider at Adaptive Biotechnologies. Learn More about Sharon Benzeno's net worth.
How old is Sharon Benzeno?: Dr. Benzeno is currently 50 years old. There are 7 older executives and no younger executives at Adaptive Biotechnologies. The oldest executive at Adaptive Biotechnologies is Ms. Stacy L. Taylor, Senior VP, General Counsel & Corporate Secretary, who is 64 years old. Learn More on Sharon Benzeno's age.
What is Sharon Benzeno's salary?: As the Insider of Adaptive Biotechnologies Co., Dr. Benzeno earns $630,720.00 per year. There are 3 executives that earn more than Dr. Benzeno. The highest earning executive at Adaptive Biotechnologies is Mr. Chad M. Robins M.B.A., Co-Founder, CEO & Chairman, who commands a salary of $1,000,000.00 per year. Learn More on Sharon Benzeno's salary.
How do I contact Sharon Benzeno?: The corporate mailing address for Dr. Benzeno and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at [email protected]. Learn More on Sharon Benzeno's contact information.
Has Sharon Benzeno been buying or selling shares of Adaptive Biotechnologies?: Sharon Benzeno has not been actively trading shares of Adaptive Biotechnologies during the past quarter. Most recently, Sharon Benzeno sold 1,354 shares of the business's stock in a transaction on Monday, March 15th. The shares were sold at an average price of $41.69, for a transaction totalling $56,448.26. Following the completion of the sale, the insider now directly owns 24,248 shares of the company's stock, valued at $1,010,899.12. Learn More on Sharon Benzeno's trading history.
Who are Adaptive Biotechnologies' active insiders?: Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Francis Lo (Insider), Jyoti Palaniappan (SVP), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.
Are insiders buying or selling shares of Adaptive Biotechnologies?: During the last twelve months, insiders at the sold shares 6 times. They sold a total of 124,555 shares worth more than $429,325.41. The most recent insider tranaction occured on November, 18th when CFO Kyle Piskel sold 248 shares worth more than $1,235.04. Insiders at Adaptive Biotechnologies own 6.2% of the company. Learn More about insider trades at Adaptive Biotechnologies.
Information on this page was last updated on 11/18/2024.

Sharon Benzeno Insider Trading History at Adaptive Biotechnologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2021	Sell	1,354	$41.69	$56,448.26	24,248
1/19/2021	Sell	417	$69.00	$28,773.00	417
1/4/2021	Sell	6,771	$57.39	$388,587.69	2,604
12/21/2020	Sell	417	$59.14	$24,661.38	417
12/1/2020	Sell	6,770	$48.87	$330,849.90	2,604
11/19/2020	Sell	416	$48.86	$20,325.76	416
11/2/2020	Sell	6,772	$45.58	$308,667.76	2,605
10/19/2020	Sell	417	$51.25	$21,371.25	417
10/1/2020	Sell	6,771	$48.57	$328,867.47	2,604
9/21/2020	Sell	417	$45.51	$18,977.67	417
9/1/2020	Sell	6,771	$41.30	$279,642.30	2,604
8/19/2020	Sell	416	$41.57	$17,293.12	416
8/4/2020	Sell	7,187	$40.00	$287,480.00	2,604
7/20/2020	Sell	417	$40.00	$16,680.00	417
7/1/2020	Sell	6,771	$47.34	$320,539.14	2,604
6/3/2020	Sell	6,770	$40.00	$270,800.00	2,604
5/26/2020	Sell	416	$42.00	$17,472.00	416

Sharon Benzeno Buying and Selling Activity at Adaptive Biotechnologies

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Today's Range

Now: $5.97

$5.81

$6.88

50 Day Range

MA: $5.43

$4.40

$6.78

2 Week Range

Now: $5.97

$2.28

$7.07

Volume

1,720,949 shs

Average Volume

1,413,251 shs

Market Capitalization

$881.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

First JFK… next Elon?

From Porter & Company | Ad

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Sharon Benzeno Biography and Net Worth

What is Sharon Benzeno's net worth?

How old is Sharon Benzeno?

What is Sharon Benzeno's salary?

How do I contact Sharon Benzeno?

Has Sharon Benzeno been buying or selling shares of Adaptive Biotechnologies?

Who are Adaptive Biotechnologies' active insiders?

Are insiders buying or selling shares of Adaptive Biotechnologies?